お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:注目市場の分析:緑内障
市場調査レポート
商品コード
570529

注目市場の分析:緑内障

Market Spotlight: Glaucoma

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 47 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
注目市場の分析:緑内障
出版日: 2021年02月11日
発行: Datamonitor Healthcare
ページ情報: 英文 47 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、緑内障の市場を調査し、疾患の背景・概要、パイプライン薬剤および上市済み薬剤の動向、臨床試験の状況、法規制・承認関連の動向、特許情報、有病率の10カ年予測、ライセンシング・買収などの取引の動向、主要薬剤の収益予測などをまとめています。

要点

疾患の背景

  • 分類

治療

  • 目薬
  • 経口投薬

疫学

パイプライン薬剤

上市済み薬剤

  • 承認:国別

今後の主要イベント

主な法規制関連意イベント

  • Aerie
  • MIXiii Biomed 2017
  • Bausch & Lomb/Nicox
  • Regeneron・Ocular
  • 新たな併用療法
  • 米国の承認動向の分析

ライセンシング・買収などの取引

  • 参天製薬・TwoXAR
  • 大塚製薬/Acucela
  • Alcon

親特許

収益機会

臨床試験環境

文献

付録

図表

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of glaucoma, 2019-28
  • Figure 2: Overview of pipeline drugs for glaucoma in the US
  • Figure 3: Pipeline drugs for glaucoma, by company
  • Figure 4: Pipeline drugs for glaucoma, by drug type
  • Figure 5: Pipeline drugs for glaucoma, by classification
  • Figure 6: AKB-9778 for Glaucoma (December 11, 2020): Phase II - OHT/OAG
  • Figure 7: Nyxol for Glaucoma (November 7, 2019): Phase II - ORION-1
  • Figure 8: NCX 470 for Glaucoma (October 2, 2019): Phase II - Dolomites
  • Figure 9: Key upcoming events in glaucoma
  • Figure 10: Probability of success in the glaucoma/ocular hypertension (ophthalmology) pipeline
  • Figure 11: Clinical trials in glaucoma
  • Figure 12: Top 10 drugs for clinical trials in glaucoma
  • Figure 13: Top 10 companies for clinical trials in glaucoma
  • Figure 14: Trial locations in glaucoma
  • Figure 15: Glaucoma trials status
  • Figure 16: Glaucoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of glaucoma, 2019-28
  • Table 2: Prevalence proportions in glaucoma, 2019-28
  • Table 3: Marketed drugs for glaucoma
  • Table 4: Pipeline drugs for glaucoma in the US
  • Table 5: AKB-9778 for Glaucoma (December 11, 2020)
  • Table 6: Nyxol for Glaucoma (November 7, 2019)
  • Table 7: NCX 470 for Glaucoma (October 2, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2021-25
目次
Product Code: DMKC0176499

Overview

This Market Spotlight report covers the Glaucoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 99.7 million prevalent cases of glaucoma in adults aged 40 years and older worldwide, and forecasts that number to increase to 119.4 million prevalent cases by 2028.

Africa is estimated to have the highest disease prevalence (4.79%), while Europe and Oceania have the lowest prevalence (2.93% and 2.97%, respectively).

The majority of approved drugs in the glaucoma space target beta adrenergic receptors or the prostaglandin F receptor. Almost all of these approved drugs are administered via the topical route, with the remainder being intraocular/subretinal/subconjunctival or oral formulations.

The highest proportion of industry-sponsored drugs in active clinical development for glaucoma are in Phase II, with only one drug in the NDA/BLA phase.

While a small number of mid-to-late-stage drugs in the glaucoma space are exploring new targets, the established target prostaglandin F receptor continues to lead clinical development. The largest number of drugs in mid-to-late-stage development for glaucoma are administered via the intraocular/subretinal/subconjunctival route.

High-impact upcoming events for drugs in the glaucoma space comprise topline Phase II trial results for GAL-101, topline Phase III trial results for NCX 470, and an expected PDUFA date for DE-117.

The overall likelihood of approval of a Phase I glaucoma/ocular hypertension (ophthalmology) asset is 4.9%, and the average probability a drug advances from Phase III is 57.1%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for glaucoma have been in the late phases of development, with 59% of trials in Phase III-IV, and 41% in Phase I-II.

The US has a substantial lead in the number of glaucoma clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the glaucoma space is dominated by completed trials. Novartis has the highest number of completed clinical trials for glaucoma, with 156 trials.

Novartis leads industry sponsors with by far the highest overall number of clinical trials for glaucoma, followed by AbbVie.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Eye drops
  • Oral medications
  • Intraocular implants

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • AKB-9778 for Glaucoma (December 11, 2020)
  • Nyxol for Glaucoma (November 7, 2019)
  • NCX 470 for Glaucoma (October 2, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Phesgo & Roclanda Among New Winners At EMA
  • Allergan's Ophthalmic Implant Technology Gets Nod For Durysta

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Upjohn To Divest Three In Australia To Complete On Viatris

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.